Neoatricon® (dopamine hydrochloride)
Hypotension in haemodynamically unstable neonates, infants, and children under 18
ApprovedActive
Key Facts
Indication
Hypotension in haemodynamically unstable neonates, infants, and children under 18
Phase
Approved
Status
Active
Company
About BrePco Biopharma
BrePco Biopharma is a commercial-stage, private biopharma company headquartered in Dublin, Ireland. It holds the EU marketing authorization for Neoatricon®, the only dopamine formulation specifically approved for pediatric use in the EU to treat hypotension in unstable neonates and children. The company is led by a small, experienced team with backgrounds in major pharma and appears to be in a revenue-generating phase, though its broader pipeline and long-term strategy beyond this single asset are not publicly disclosed. Its business model is centered on therapeutics, specifically addressing a critical unmet need in pediatric intensive care.
View full company profile